THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [10.19] ID: TIP-MED-000203

Sodium Bicarbonate (Oral Enteric/Uncoated for CKD Metabolic Acidosis)

Active Ingredient / Scientific Identity: Sodium Bicarbonate • Class: Systemic Alkalinising Buffer for Chronic Kidney Disease Metabolic Acidosis (Schedule H / OTC | NLEM 2022)

⚖️ Compare Profile
Generic / Entity NameSodium Bicarbonate (Oral Enteric/Uncoated for CKD Metabolic Acidosis) ([10.19])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassSystemic Alkalinising Buffer for Chronic Kidney Disease Metabolic Acidosis (Schedule H / O
Available Dosage FormsUncoated / Enteric-Coated Tablets: 500 mg, 1000 mg (1 g) (1000 mg NaHCO3 = 11.9 mEq of HCO3- and 11.9 mEq [274
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Specifically indicated in CKD Stage 3b–5 when Serum HCO3- <18–22 mEq/L. Hepatic: Caution in cirrhotic ascites due to s
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Sodium Bicarbonate (Oral Enteric/Uncoated for CKD Metabolic Acidosis) (TIP-MED-000203, Reference Code [10.19]) is classified under Vitamins, Minerals & Nutrition — CKD-MBD & Electrolyte Binders/Buffers (Ch 10) as a Systemic Alkalinising Buffer for Chronic Kidney Disease Metabolic Acidosis (Schedule H / OTC | NLEM 2022). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.19], p. 136): Sobosis / Sobosis Forte (La Renon), Nodosis / Nodosis DS (Steadfast), Sodamint — Strengths & Dosage Forms: Uncoated / Enteric-Coated Tablets: 500 mg, 1000 mg (1 g) (1000 mg NaHCO3 = 11.9 mEq of HCO3- and 11.9 mEq [274 mg] of elemental Sodium [Na+]!); IV Ampoule: 8.4% w/v (1 mEq/mL)
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.19], p. 136): Sobosis / Sobosis Forte (La Renon), Nodosis / Nodosis DS (Steadfast), Sodamint — Strengths & Dosage Forms: Uncoated / Enteric-Coated Tablets: 500 mg, 1000 mg (1 g) (1000 mg NaHCO3 = 11.9 mEq of HCO3- and 11.9 mEq [274 mg] of elemental Sodium [Na+]!); IV Ampoule: 8.4% w/v (1 mEq/mL)
Dosage Forms & Available Strengths:
Uncoated / Enteric-Coated Tablets: 500 mg, 1000 mg (1 g) (1000 mg NaHCO3 = 11.9 mEq of HCO3- and 11.9 mEq [274 mg] of elemental Sodium [Na+]!); IV Ampoule: 8.4% w/v (1 mEq/mL)
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Systemic Alkalinising Buffer for Chronic Kidney Disease Metabolic Acidosis (Schedule H / OTC | NLEM 2022) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutrition — CKD-MBD & Electrolyte Binders/Buffers (Ch 10): clinical efficacy is mediated via Systemic Alkalinising Buffer for Chronic Kidney Disease Metabolic Acidosis (Schedule H / OTC | NLEM 2022) for Correction of chronic metabolic acidosis in CKD Stage 3b–5 when Serum Bicarbonate (HCO3-) falls <18–22 mEq/L (KDIGO 2024: chronic acidosis accelerates GFR loss, causes muscle catabolism, demineralises bone, and worsens hyperkalaemia!); urinary alkalinisation.

4. Therapeutic Indications & Evidence-Supported Uses

  • Correction of chronic metabolic acidosis in CKD Stage 3b–5 when Serum Bicarbonate (HCO3-) falls <18–22 mEq/L (KDIGO 2024: chronic acidosis accelerates GFR loss, causes muscle catabolism, demineralises bone, and worsens hyperkalaemia!)
  • urinary alkalinisation

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: CKD Metabolic Acidosis: Start 500 mg PO BD–TDS (1.5 g/day), titrate to 500–1000 mg BD–TDS (up to 2–3 g/day) to maintain Serum Bicarbonate in the normal physiological range of 22–26 mEq/L

Administration & Meal Timing: Take 1–2 hours AFTER meals (taking uncoated Sodium Bicarbonate directly with a large meal neutralises gastric HCl, releases CO2 gas causing belching/gastric distension, and alters pH-dependent absorption of other drugs! Enteric-coated Sobosis/Nodosis EC reduces bloating) | 1–2 Hours After Breakfast, Lunch & Dinner (BD or TDS)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Specifically indicated in CKD Stage 3b–5 when Serum HCO3- <18–22 mEq/L. Hepatic: Caution in cirrhotic ascites due to sodium load
Elimination & Renal Adjustment:
Renal: Specifically indicated in CKD Stage 3b–5 when Serum HCO3- <18–22 mEq/L. Hepatic: Caution in cirrhotic ascites due to sodium load
Hepatic Impairment Considerations:
Renal: Specifically indicated in CKD Stage 3b–5 when Serum HCO3- <18–22 mEq/L. Hepatic: Caution in cirrhotic ascites due to sodium load

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindicated in metabolic or respiratory alkalosis (Serum HCO3- >28 mEq/L), severe uncontrolled hypertension, decompensated congestive heart failure / pulmonary oedema, anuric fluid overload, and hypocalcaemia. Each 1000 mg tablet delivers 274 mg of Sodium!

Key Clinical Precautions: Renal: Specifically indicated in CKD Stage 3b–5 when Serum HCO3- <18–22 mEq/L. Hepatic: Caution in cirrhotic ascites due to sodium load

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Abdominal bloating, belching/eructation, flatulence (markedly reduced by using Enteric-Coated tablets!), ankle oedema, mild blood pressure elevation
  • Fluid overload / pulmonary oedema and worsening hypertension (from sodium load in CKD/HF), metabolic alkalosis (Serum HCO3- >28–30 mEq/L -> accelerates vascular calcification & precipitates hypocalcaemic tetany!), hypokalaemia
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • ALTERS GI pH AND URINARY pH: (1) Raises gastric pH -> reduces absorption of Oral Iron, Ketoconazole/Itraconazole, Cefuroxime/Cefpodoxime, and causes premature gastric dissolution of Enteric-Coated Bisacodyl or Mesalazine (separate by >=2 hours from all other oral medicines!); (2) Alkalinises urine -> increases renal excretion of Lithium and Salicylates/Methotrexate, and decreases excretion of Memantine/Quinidine

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Protects your kidneys, muscles, and bones from acid buildup in CKD; take 1–2 hours after meals and space at least 2 hours apart from Iron, Calcium, or other tablets; reduce added salt in your cooking and monitor your blood pressure and ankle swelling
  • Meal & Clock Timing Instruction: Take 1–2 hours AFTER meals (taking uncoated Sodium Bicarbonate directly with a large meal neutralises gastric HCl, releases CO2 gas causing belching/gastric distension, and alters pH-dependent absorption of other drugs! Enteric-coated Sobosis/Nodosis EC reduces bloating) (1–2 Hours After Breakfast, Lunch & Dinner (BD or TDS))
  • Missed Dose Protocol: Take 1–2 hours after next meal if remembered; do not double dose
  • Geriatric Dispensing Pearl: Monitor blood pressure and fluid status (ankle oedema/dyspnoea) closely in older CKD patients with concurrent heart failure

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Uncoated / Enteric-Coated Tablets: 500 mg, 1000 mg (1 g) (1000 mg NaHCO3 = 11.9 mEq of HCO3- and 11.9 mEq [274 mg] of elemental Sodium [Na+]!); IV Ampoule: 8.4% w/v (1 mEq/mL)

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 10 [10.19] (p. 136)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.